1879 Impact of adjuvant trastuzumab (adjT) for early-stage (ES) breast cancer (BC) on clinical characteristics, survival and likelihood of durable complete response (DCR) of HER2-positive (HER2+) metastatic breast cancer (MBC): A 15-year single-institution cohort study. (September 2015) - Zacchia, A.; Gullo, G.; Parker, I.; De Giorgi, A.; Fennelly, D.; Zanoni, D.; Walshe, J.; Defrein, A.M.; Quinn, C.; Silva, N.; O' Donovan, N.; Ballot, J.; et al.